NUVL (Nuvalent Inc) Earnings per share for the last four quarters

Public company logo of Nuvalent Inc (NUVL)

The rolling year net income per share trend helps assess the impact of global cooperation and component logistics on the Nuvalent, Inc. (NUVL) strategy. Low geopolitical risks and patent protection in the US create a reliable foundation, although business success depends on regulatory approvals and clinical phases. The value of -37.70 characterizes this level, allowing the market to filter out noise and identify the real fundamental momentum.

NUVL nuvalent.com Earnings per share for the last twelve months (02/11/2024 - 07/25/2026)

Nuvalent Inc - analytical breakdowns and key metrics (NUVL)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:Nuvalent (NUVL)
Signature product of Nuvalent

This indicator measures the trailing twelve-month (TTM) net income per share dynamics, allowing for an assessment of business scaling rates relative to previous periods. By analyzing the annual EPS growth rate (TTM), an investor compares the financial efficiency of Nuvalent, Inc. (NUVL) against stringent FDA regulatory oversight and the complexity of developing proprietary oncology drugs.

Competitor analysis for Nuvalent, Inc.

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) enliventherapeutics.com|Earnings per share for the last twelve months ORIC Pharmaceuticals, Inc. (ORIC)|RLAY (Relay Therapeutics, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics Inc)|Net earnings per share for the trailing year Tyra Bio|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX